Vasculogenic mimicry correlates to presenting symptoms and mortality in uveal melanoma.


Journal

Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 13 10 2021
accepted: 04 11 2021
pubmed: 15 11 2021
medline: 8 3 2022
entrez: 14 11 2021
Statut: ppublish

Résumé

Fluid-conducting extracellular matrix patterns known as vasculogenic mimicry (VM) have been associated with poor prognosis in uveal melanoma and other cancers. We investigate the correlations between VM, presenting symptoms, mortality, and the area density of periodic acid-Schiff positive histological patterns (PAS density). Sixty-nine patients that underwent enucleation for uveal melanoma between 2000 and 2007 were included. Clinicopathological parameters presenting symptoms and outcomes were collected. Histological tumor sections were evaluated for VM and PAS density was quantified with digital image analysis. Thirty-four patients (49%) presented with blurred vision. 18 (26%) with a shadow in the visual field, 7 (10%) with photopsia and/or floaters, and 2 (3%) with metamorphopsia. Nine patients (13%) had no symptoms at all. Median follow-up was 16.7 years (SD 2.6). A shadow in the visual field, but no other symptom, was positively correlated with the presence of VM (φ 0.70, p < 0.001) and greater PAS density (p < 0.001). In multivariate regression, retinal detachment (RD), presence of VM, and PAS density ≥ median were independent predictors of a shadow, but not tumor distance to the macula, tumor apical thickness, tumor diameter, or ciliary body engagement. The presence of VM was associated with significantly shorter cumulative disease-specific survival (Wilcoxon p = 0.04), but not PAS density ≥ median, presenting symptoms or RD (p > 0.28). Tumors from uveal melanoma patients that report a visual field shadow are likely to display VM and greater PAS density, likely explaining the previously reported association between this symptom and poor prognosis.

Identifiants

pubmed: 34775516
doi: 10.1007/s00432-021-03851-9
pii: 10.1007/s00432-021-03851-9
pmc: PMC8881423
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

587-597

Subventions

Organisme : Royal Swedish Academy of Sciences
ID : ME2019-0036
Organisme : Cancerfonden
ID : 20 0798 Fk
Organisme : Svenska Läkaresällskapet
ID : Cronqvists stiftelse
Organisme : Svenska Läkaresällskapet
ID : SLS 934014
Organisme : Ögonfonden
ID : 2020-04-27
Organisme : Karolinska Institutet
ID : 2020-013333
Organisme : Karolinska Institutet
ID : 2020-02517
Organisme : Region Stockholm
ID : 20200356
Organisme : Stiftelsen Kronprinsessan Margaretas Arbetsnämnd för Synskadade
ID : 157
Organisme : Carmen and Bertil Regnér Foundation
ID : 2020-00062

Informations de copyright

© 2021. The Author(s).

Références

Br J Ophthalmol. 2021 Apr;105(4):582-586
pubmed: 32522791
Can J Ophthalmol. 2004 Jun;39(4):409-21
pubmed: 15327107
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Ann Oncol. 2019 Aug 1;30(8):1370-1380
pubmed: 31150059
Ophthalmology. 2012 Aug;119(8):1596-603
pubmed: 22521086
Sci Rep. 2020 Jul 9;10(1):11297
pubmed: 32647177
Ophthalmology. 2012 Aug;119(8):1582-9
pubmed: 22503229
Science. 2010 Dec 3;330(6009):1410-3
pubmed: 21051595
Ophthalmology. 2021 Jul;128(7):1107-1109
pubmed: 33253758
Ocul Oncol Pathol. 2020 Mar;6(2):129-137
pubmed: 32258021
Micron. 2003;34(8):365-72
pubmed: 14680922
Methods Mol Biol. 2017;1639:145-149
pubmed: 28752454
Nat Commun. 2020 Apr 20;11(1):1894
pubmed: 32313009
Curr Eye Res. 2003 Oct;27(4):237-45
pubmed: 14562175
Eur J Cancer. 2013 Dec;49(18):3914-23
pubmed: 23992642
Sci Rep. 2021 Apr 26;11(1):8923
pubmed: 33903674
Mol Vis. 2019 Sep 21;25:502-516
pubmed: 31588174
Arch Ophthalmol. 2006 Dec;124(12):1684-93
pubmed: 17159027
Eye (Lond). 2007 Jun;21(6):752-9
pubmed: 16575415
Br J Ophthalmol. 1997 Sep;81(9):748-54
pubmed: 9422926
Arch Pathol Lab Med. 1998 Apr;122(4):353-60
pubmed: 9648905
APMIS. 2004 Jul-Aug;112(7-8):508-25
pubmed: 15563313
Cancers (Basel). 2020 Dec 21;12(12):
pubmed: 33371395
Ophthalmology. 1997 May;104(5):777-80
pubmed: 9160022
Melanoma Res. 2019 Dec;29(6):561-568
pubmed: 30664106
Front Oncol. 2020 Oct 13;10:562074
pubmed: 33154942
Eye (Lond). 2012 Feb;26(2):292-9
pubmed: 22079972
Cancer Res. 1996 Jul 1;56(13):2900-3
pubmed: 8674036
J Natl Cancer Inst. 1999 Feb 17;91(4):359-67
pubmed: 10050870
Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2471-80
pubmed: 10509639
Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2085-93
pubmed: 11481276
Pathol Oncol Res. 1996;2(4):229-236
pubmed: 11173608
Ophthalmology. 2001 May;108(5):829-31
pubmed: 11319992
Hum Pathol. 1992 Nov;23(11):1298-305
pubmed: 1427757
Br J Ophthalmol. 2021 Jan 15;:
pubmed: 33452185
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9
pubmed: 14578381
Ophthalmology. 1992 May;99(5):767-73; discussion 774
pubmed: 1594224
Br J Ophthalmol. 1997 Mar;81(3):240-6; discussion 247-8
pubmed: 9135390
Lancet. 2011 May 28;377(9780):1890
pubmed: 21621718
JAMA Ophthalmol. 2016 Jul 1;134(7):728-33
pubmed: 27123562

Auteurs

Shiva Sabazade (S)

St. Erik Eye Hospital, Stockholm, Sweden.
Department of Clinical Neuroscience, Karolinska Institutet, Eugeniavägen 12, 17164, Stockholm, Sweden.

Viktor Gill (V)

Department of Clinical Neuroscience, Karolinska Institutet, Eugeniavägen 12, 17164, Stockholm, Sweden.
Department of Pathology, Västmanland Hospital Västerås, Västerås, Sweden.

Christina Herrspiegel (C)

St. Erik Eye Hospital, Stockholm, Sweden.
Department of Clinical Neuroscience, Karolinska Institutet, Eugeniavägen 12, 17164, Stockholm, Sweden.

Gustav Stålhammar (G)

St. Erik Eye Hospital, Stockholm, Sweden. gustav.stalhammar@ki.se.
Department of Clinical Neuroscience, Karolinska Institutet, Eugeniavägen 12, 17164, Stockholm, Sweden. gustav.stalhammar@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH